curb glp 1 Modere | Burn, Curb, Sculpt | Modere A miracle drug that curbs

Glucose-dependent insulinotropic polypeptide (GIP) Combining GLP-1 with its incretin partner GIP is a promising strategy (Figure 2) under investigation for treating T2D and obesity

Funding This work was supported by Statutory Funds of the Laboratory of Immunoendocrinology, Maj Institute of Pharmacology, Cracow, Poland

Data are regularly updating

Prospective studies will be needed to determine whether semaglutide truly increases the risk of NAION, and whether certain formulations, doses, or patient groups are particularly vulnerable

Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs